| Name: |
AEOL-10150 |
|---|
| Synonyms: |
Mn(III) tetrakis(N,N'-
diethylimidazolium-2-yl) porphyrin[1]
MnTDE-2-ImP5+[1]
|
|---|
| Trade name: |
Molecule is developed by Aeolus Pharmaceuticals, Inc., CA, USA[2]
|
|---|
| Chemical name: |
|
|---|
| Molecular Weight: |
|
|---|
| Source: |
|
| Structure: |
 [3],[4]
|
| Chemical Nature: |
AEOL-10150 is a small-molecule antioxidant analogous to the catalytic site of superoxide dismutase.[2]
AEOL 10150 is positively charged, and the positive charges are present
on the four pyridyl or imidizol groups in the compound.[5]
|
| Actions & Indications: |
Pharmcological Action-
Therapeutic indications:
Preclinical study-
|
| Notes: |
|
| REFERENCES |
| 1. |
Chapter 27: Superoxide dismutase mimics and other redox-active therapeutics by Haberle IB, Tovmasyan A; In :Oxidative Stress and Antioxidant Protection: The Science of Free Radical Biology and Disease, edited by Armstrong D, Stratton RD, John Wiley and Sons, 2016, page no. 416.
https://books.google.co.in/books?id=mAT9CgAAQBAJ&pg=PA416 |
| 2. |
Orrell RW, AEOL-10150 (Aeolus). Curr Opin Investig Drugs. 2006;7(1):70-80.
https://www.ncbi.nlm.nih.gov/pubmed/16425674 |
| 3. |
Day BJ, Catalytic antioxidants: a radical
approach to new therapeutics. Drug Discov Today. 2004;9(13):557-66.
http://dx.doi.org/10.1016/S1359-6446(04)03139-3 |
| 4. |
Garofalo MC et al, A Pilot study in Rhesus Macaques to assess the treatment efficacy of a small molecular weight catalytic metalloporphyrin antioxidant (AEOL 10150) in mitigating radiation-induced lung damage. Health Phys. 2014; 106 (1): 73-83.
http://dx.doi.org/10.1097/HP.0b013e3182a4d967 |
| 5. |
Crapo JD, Oxidative stress as an initiator of cytokine release and cell damage. Eur Respir J 2003; 22: Suppl. 44, 4s–6s.
http://dx.doi.org/10.1183/09031936.03.00000203a |
